We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
If You Invested $1000 in Medpace a Decade Ago, This is How Much It'd Be Worth Now
Read MoreHide Full Article
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well.
Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks.
What if you'd invested in Medpace (MEDP - Free Report) ten years ago? It may not have been easy to hold on to MEDP for all that time, but if you did, how much would your investment be worth today?
Medpace's Business In-Depth
With that in mind, let's take a look at Medpace's main business drivers.
Medpace Holdings, Inc. is a global clinical contract research organization (CRO) delivering full-service Phase I-IV drug and device development support, including protocol and project management, regulatory affairs, clinical monitoring, data management/analysis, pharmacovigilance, submission support, and specialized services such as bioanalytical labs and medical imaging. The company is headquartered in Cincinnati, OH, and employed approximately 6,600 people across 46 countries as of Sept. 30, 2026.
The firm serves all major therapeutic areas with particular depth in Oncology, Metabolic Disease, Cardiology, Central Nervous System (“CNS”), and Antiviral and Anti-infective work. Its operations are principally based in North America, Europe and Asia. Medpace uses a centralized operating model, proprietary technology and local regulatory expertise to support consistent study execution.
The company reports a single operating segment because its full-service platform is managed and evaluated on a consolidated basis. Net revenue was $2.5 billion in fiscal 2025, up roughly 20% year over year from 2024.
The United States accounted for roughly 99% of consolidated revenues in fiscal 2025 based on contracting entity location. Client mix remains concentrated in small biopharma and mid-sized biopharma, which represented 82% and 13% of fiscal 2025 net revenues, respectively.
Commercial metrics include net new business awards, cancellations, backlog and backlog conversion. Net new business awards were $2.6 billion in fiscal 2025 versus $2.2 billion in 2024. Backlog represents anticipated future net revenue from awarded work that has not yet commenced or is in progress but remains incomplete. It is affected by new awards, scope changes, cancellations, revenue recognition and foreign exchange. As of September 30, 2026, backlog totaled $3.17 billion, with approximately $1.99 billion expected to convert into revenue over the following 12 months.
Bottom Line
Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For Medpace, if you bought shares a decade ago, you're likely feeling really good about your investment today.
A $1000 investment made in November 2016 would be worth $20,503.07, or a 1,950.31% gain, as of November 6, 2026, according to our calculations. Investors should note that this return excludes dividends but includes price increases.
The S&P 500 rose 252.67% and the price of gold increased 203.70% over the same time frame in comparison.
Analysts are anticipating more upside for MEDP.
Medpace's full-service model supports dependable margins and financial flexibility as its therapeutic mix evolves. Record third-quarter awards, favorable win rates and a larger pipeline of pending decisions improve the outlook for backlog growth. Lower pass-through costs and disciplined staffing also support profitability and reinvestment capacity. However, revenue growth has moderated despite healthier bookings, while cancellations remain unpredictable. Oncology is regaining share as metabolic awards slow, leaving the timing of new study revenue uncertain. Customer concentration, pre-backlog delays and quarterly margin variability limit visibility. Planned campus costs could also restrain 2027 profitability. Together, these factors leave a balanced investment outlook despite improved commercial execution.
The stock is up 5.36% over the past four weeks, and no earnings estimate has gone lower in the past two months, compared to 4 higher, for fiscal 2026. The consensus estimate has moved up as well.
View the Zacks #1 Rank List
Image: Bigstock
If You Invested $1000 in Medpace a Decade Ago, This is How Much It'd Be Worth Now
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well.
Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks.
What if you'd invested in Medpace (MEDP - Free Report) ten years ago? It may not have been easy to hold on to MEDP for all that time, but if you did, how much would your investment be worth today?
Medpace's Business In-Depth
With that in mind, let's take a look at Medpace's main business drivers.
Medpace Holdings, Inc. is a global clinical contract research organization (CRO) delivering full-service Phase I-IV drug and device development support, including protocol and project management, regulatory affairs, clinical monitoring, data management/analysis, pharmacovigilance, submission support, and specialized services such as bioanalytical labs and medical imaging. The company is headquartered in Cincinnati, OH, and employed approximately 6,600 people across 46 countries as of Sept. 30, 2026.
The firm serves all major therapeutic areas with particular depth in Oncology, Metabolic Disease, Cardiology, Central Nervous System (“CNS”), and Antiviral and Anti-infective work. Its operations are principally based in North America, Europe and Asia. Medpace uses a centralized operating model, proprietary technology and local regulatory expertise to support consistent study execution.
The company reports a single operating segment because its full-service platform is managed and evaluated on a consolidated basis. Net revenue was $2.5 billion in fiscal 2025, up roughly 20% year over year from 2024.
The United States accounted for roughly 99% of consolidated revenues in fiscal 2025 based on contracting entity location. Client mix remains concentrated in small biopharma and mid-sized biopharma, which represented 82% and 13% of fiscal 2025 net revenues, respectively.
Commercial metrics include net new business awards, cancellations, backlog and backlog conversion. Net new business awards were $2.6 billion in fiscal 2025 versus $2.2 billion in 2024. Backlog represents anticipated future net revenue from awarded work that has not yet commenced or is in progress but remains incomplete. It is affected by new awards, scope changes, cancellations, revenue recognition and foreign exchange. As of September 30, 2026, backlog totaled $3.17 billion, with approximately $1.99 billion expected to convert into revenue over the following 12 months.
Bottom Line
Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For Medpace, if you bought shares a decade ago, you're likely feeling really good about your investment today.
A $1000 investment made in November 2016 would be worth $20,503.07, or a 1,950.31% gain, as of November 6, 2026, according to our calculations. Investors should note that this return excludes dividends but includes price increases.
The S&P 500 rose 252.67% and the price of gold increased 203.70% over the same time frame in comparison.
Analysts are anticipating more upside for MEDP.
Medpace's full-service model supports dependable margins and financial flexibility as its therapeutic mix evolves. Record third-quarter awards, favorable win rates and a larger pipeline of pending decisions improve the outlook for backlog growth. Lower pass-through costs and disciplined staffing also support profitability and reinvestment capacity. However, revenue growth has moderated despite healthier bookings, while cancellations remain unpredictable. Oncology is regaining share as metabolic awards slow, leaving the timing of new study revenue uncertain. Customer concentration, pre-backlog delays and quarterly margin variability limit visibility. Planned campus costs could also restrain 2027 profitability. Together, these factors leave a balanced investment outlook despite improved commercial execution.
The stock is up 5.36% over the past four weeks, and no earnings estimate has gone lower in the past two months, compared to 4 higher, for fiscal 2026. The consensus estimate has moved up as well.